Invest Well in Amgen Stock: Products, Dividend, Financial Statements, and More
2024-04-07 updated
When making long-term investments to ensure stability through diversified investments, it is recommended to prioritize ETFs that include Amgen stocks. However, there might still be individuals who wish to invest directly in Amgen stocks. Shall we also explore a value investing approach to assess whether Amgen's performance will grow in the long term?
Q. What products and services does Amgen provide?
Pharmaceuticals
Biological Products
- Amgen develops and sells pharmaceuticals for various diseases such as cancer, cardiovascular disease, bone disease, and immune disease.
- Amgen develops and sells various biological products such as antibodies, proteins, and cell therapies.
Q. Is Amgen's executive CEO honest and competent?
Robert A. Bradway is the CEO of Amgen.
- Appointed CEO of Amgen in May 2012.
- Served as President and Chief Operating Officer of Amgen from 2010 to 2012.
- Joined Amgen in 2006.
- Served as Managing Director at Morgan Stanley in London before joining Amgen.
- Master of Business Administration from Harvard University
- Bachelor of Arts in Biology from Amherst College
Q. Is Amgen's financial statements healthy?
(2024년 04월 06일 기준)
Net Profit Margin
- Amgen has earned an annual net profit equivalent to 4.60% of the current stock price.
- Thenet profit has been decreasingat an annual rate of -4.36% over the past 5 years, so it's something to be cautious about.
Total Debt
- The debt is 923.85% of the annual net profit.
- It would take about 10 years for the company to repay all of its debt.
- The net profit is decreasing, so Amgen should be careful about managing the debt.
Dividend
- Amgen offers a 3.33% annual dividend.
- Over the past 5 years, the annual average dividend has grown by 9.17%.
- Dividends are growing, which is good.
Q. What is Amgen's stock performance like?
- This year's total return is 20.21%.
- 5-year mean total return is 10.37%.
Q. When is a good time to buy and sell Amgen?
If Amgen is healthy and growing, it will rise in the long run, so it is good to buy in installments even if you think the current stock price is a bit high. On the other hand, if you think that Amgen is no longer healthy in the long run, you can consider selling.
PER
- Current: 21.61
- 5Y Avg: 19.73
- The current value is higher than the average, so be careful when buying. However, purchasing can be considered only if you judge that the company will sustain high long-term growth.
Price/Sale Ratio
- Current: 5.18
- 5Y Avg: 5.23
- Current value is lower than average so it may be time to consider buying. However, this strategy is only recommended if you are convinced that the company will continue to be healthy and grow in the long term.
#Long-term value investing in Amgen#Intrinsic value of Amgen#Introduction and analysis of stock#forecast#products#competitiveness#management CEO#financial statements#net income#debt#ROIC#dividend#treasury stock#return#PER#Price/Sale Ratio#philosophy#fundamental analysis
Value Investing Together is a blog and application that provides stock information for individuals interested in value investing and is not intended for investment recommendations. The information provided should only be used for reference purposes, and investment decisions should be made at one's own discretion and responsibility.